111 related articles for article (PubMed ID: 15491730)
1. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Gandhok N; Sartor O
Urology; 2004 Oct; 64(4):807-9. PubMed ID: 15491730
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
4. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
5. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
6. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
11. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.
Turner J; Chaudhary U
Anticancer Drugs; 2009 Mar; 20(3):215-6. PubMed ID: 19104437
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
13. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
16. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G
Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522
[TBL] [Abstract][Full Text] [Related]
18. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
19. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
